Natera (NASDAQ:NTRA) CFO Sells 781 Shares of Stock

Key Points

• Natera CFO Michael Brophy sold 781 shares at an average price of $406, generating $317,086. The transaction was conducted under a pre-arranged Rule 10b5-1 plan to cover tax withholding, leaving him with 50,856 shares.
• Natera shares rose 2.7% to $436, near their 52-week high. The company’s latest quarterly results exceeded expectations, with revenue of $752.75 million—up 37.7% year over year—and a smaller-than-expected loss.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $394.31, although ratings range from “Strong Sell” to “Overweight.” Institutional investors own approximately 99.9% of the stock.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Brophy sold 781 shares of the firm's stock in a transaction that occurred on Tuesday, October 27th. The stock was sold at an average price of $406.00, for a total transaction of $317,086.00. Following the sale, the chief financial officer owned 50,856 shares of the company's stock, valued at approximately $20,647,536. This represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, October 28th, Michael Brophy sold 1,198 shares of Natera stock. The shares were sold at an average price of $426.34, for a total transaction of $510,755.32.
• On Tuesday, August 4th, Michael Brophy sold 478 shares of Natera stock. The stock was sold at an average price of $274.22, for a total transaction of $131,077.16.
• On Monday, August 3rd, Michael Brophy sold 317 shares of Natera stock. The stock was sold at an average price of $267.99, for a total transaction of $84,952.83.

Natera Trading Up 2.7%

Shares of NASDAQ:NTRA traded up $11.58 during trading on Thursday, reaching $436.00. 1,325,469 shares of the company traded hands, compared to its average volume of 1,585,948. The firm has a fifty day simple moving average of $375.27 and a 200 day simple moving average of $265.54. Natera, Inc. has a 1-year low of $181.00 and a 1-year high of $437.41.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. Natera's quarterly revenue was up 37.7% compared to the same quarter last year. During the same period last year, the company earned ($0.74) earnings per share. On average, equities analysts expect that Natera, Inc. will post -1.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of NTRA. BlackRock Inc. bought a new stake in Natera during the second quarter valued at about $2,962,770,000. K.J. Harrison & Partners Inc bought a new position in shares of Natera in the second quarter worth about $5,117,000. Abbot Financial Management Inc. bought a new position in shares of Natera in the second quarter worth about $1,537,000. Eagle Health Investments LP bought a new position in shares of Natera in the second quarter worth about $4,302,000. Finally, BlueCrest Capital Management Ltd acquired a new position in shares of Natera during the 2nd quarter worth about $11,695,000. Institutional investors own 99.90% of the company's stock.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera presented 25 abstracts at the ESMO oncology conference, highlighting additional Signatera data and supporting the test’s potential commercial and clinical adoption. Natera presents 25 ESMO abstracts
• Positive Sentiment: Investors reacted favorably to Signatera clinical and regulatory wins, which could strengthen Natera’s competitive position in minimal residual disease testing and support future revenue growth. Investors React to Signatera Wins
• Positive Sentiment: The third-quarter outlook centers on continued Signatera volume growth, higher test prices, regulatory progress and expanding Medicare coverage that could benefit Natera’s organ-health business. NTRA Q3 Earnings Preview
• Neutral Sentiment: Natera will release third-quarter 2026 results on November 5 after the market closes, giving investors a near-term catalyst to assess testing volumes, reimbursement trends and profitability. Natera Q3 Results Announcement
• Negative Sentiment: Zacks cautions that Natera may report negative earnings and lacks the typical combination of estimate revisions and momentum associated with a likely earnings beat, raising the risk of volatility around the report. Natera Earnings Beat Outlook
• Negative Sentiment: One valuation analysis estimates NTRA could be about 32% below fair value based on ESMO-related data, suggesting the stock’s gains may have outpaced its fundamentals. Natera Fair Value Analysis
• Negative Sentiment: Two company officers disclosed plans to sell a combined 1,768 shares, including 771 shares valued at approximately $312,000; the transactions are relatively small but may modestly weigh on sentiment. John Fesko Share Sale Solomon Moshkevich Share Sale

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on NTRA shares. Morgan Stanley lifted their price target on Natera from $355.00 to $435.00 and gave the company an "overweight" rating in a report on Monday, October 12th. Wells Fargo & Company lifted their target price on shares of Natera from $220.00 to $284.00 and gave the company an "equal weight" rating in a research note on Friday, August 7th. JPMorgan Chase & Co. boosted their target price on shares of Natera from $360.00 to $460.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 14th. TD Cowen raised their price target on shares of Natera from $340.00 to $480.00 and gave the company a "buy" rating in a report on Tuesday, October 13th. Finally, Zacks Research downgraded shares of Natera from a "hold" rating to a "strong sell" rating in a report on Friday, October 16th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $394.31.

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.